Oxytocin receptor is a promising therapeutic target of malignant mesothelioma.
Animals
Biomarkers, Tumor
/ antagonists & inhibitors
Cell Line, Tumor
Cell Proliferation
/ drug effects
Female
Gene Knockdown Techniques
HEK293 Cells
Humans
Mesothelioma, Malignant
/ drug therapy
Mice
Mice, Inbred BALB C
Mice, Nude
Oxytocin
/ pharmacology
Pyridines
/ administration & dosage
RNA, Messenger
/ genetics
Receptors, Oxytocin
/ antagonists & inhibitors
Transfection
Treatment Outcome
Triazoles
/ administration & dosage
Tumor Burden
/ drug effects
Xenograft Model Antitumor Assays
G-protein-coupled receptors
G1 phase cell cycle checkpoints
malignant mesothelioma
oxytocin receptor
oxytocin receptor antagonists
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
revised:
10
06
2021
received:
22
02
2021
accepted:
10
06
2021
pubmed:
12
6
2021
medline:
15
9
2021
entrez:
11
6
2021
Statut:
ppublish
Résumé
Malignant mesothelioma (MM) is one of the most aggressive tumors. We conducted bioinformatics analysis using Cancer Cell Line Encyclopedia (CCLE) datasets to identify new molecular markers in MM. Overexpression of oxytocin receptor (OXTR), which is a G-protein-coupled receptor for the hormone and neurotransmitter oxytocin, mRNA was distinctively identified in MM cell lines. Therefore, we assessed the role of OXTR and its clinical relevance in MM. Kaplan-Meier and Cox regression analyses were applied to assess the association between overall survival and OXTR mRNA expression using The Cancer Genome Atlas (TCGA) datasets. The function of OXTR and the efficacy of its antagonists were investigated in vitro and in vivo using MM cell lines. Consistent with the findings from CCLE datasets analysis, OXTR mRNA expression was highly increased in MM tissues compared with other cancer types in the TCGA datasets, and MM cases with high OXTR expression showed poor overall survival. Moreover, OXTR knockdown dramatically decreased MM cell proliferation in cells with high OXTR expression via tumor cell cycle disturbance, whereas oxytocin treatment significantly increased MM cell growth. OXTR antagonists, which have high selectivity for OXTR, inhibited the growth of MM cell lines with high OXTR expression, and oral administration of the OXTR antagonist, cligosiban, significantly suppressed MM tumor progression in a xenograft model. Our findings suggest that OXTR plays a crucial role in MM cell proliferation and is a promising therapeutic target that may broaden potential therapeutic options and could be a prognostic biomarker of MM.
Identifiants
pubmed: 34115916
doi: 10.1111/cas.15025
pmc: PMC8409407
doi:
Substances chimiques
Biomarkers, Tumor
0
OXTR protein, human
0
Pyridines
0
RNA, Messenger
0
Receptors, Oxytocin
0
Triazoles
0
Oxytocin
50-56-6
cligosiban
D361S17AIF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3520-3532Subventions
Organisme : Japan Society for the Promotion of Science
ID : Grant-in-Aid for Scientific Research (B) 20H03
Organisme : The Nitto Foundation
ID : Nitto Foundation
Organisme : Japan Agency for Medical Research and Development
ID : Grant Number (JP 20lm0203005j0004)
Informations de copyright
© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Sex Med. 2019 Feb;16(2):213-222
pubmed: 30612858
Semin Oncol. 2002 Feb;29(1):2-17
pubmed: 11836664
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Cancer Sci. 2021 Sep;112(9):3520-3532
pubmed: 34115916
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Biol Chem. 2005 Apr 22;280(16):16311-8
pubmed: 15705593
Br J Cancer. 2014 Jan 21;110(2):510-9
pubmed: 24327015
Occup Environ Med. 2017 Dec;74(12):851-858
pubmed: 28866609
Curr Opin Cell Biol. 2009 Dec;21(6):837-43
pubmed: 19846288
World J Clin Oncol. 2018 Sep 14;9(5):74-82
pubmed: 30254962
Nat Protoc. 2009;4(4):495-505
pubmed: 19300443
Int J Mol Sci. 2018 Mar 26;19(4):
pubmed: 29587439
Mol Cell Biol. 1999 Jan;19(1):612-22
pubmed: 9858585
BMC Med. 2009 Oct 22;7:62
pubmed: 19845972
J Sex Med. 2019 Aug;16(8):1188-1198
pubmed: 31351660
Eur Respir Rev. 2015 Mar;24(135):115-31
pubmed: 25726562
Curr Protoc Hum Genet. 2007 Jan;Chapter 12:Unit 12.7
pubmed: 18428407
Lung Cancer. 2010 Dec;70(3):271-9
pubmed: 20371132
J Clin Endocrinol Metab. 1981 Oct;53(4):730-3
pubmed: 7287862
J Med Microbiol. 1991 Nov;35(5):291-3
pubmed: 1941999
J Clin Oncol. 2006 Mar 20;24(9):1443-8
pubmed: 16549838
J Thorac Oncol. 2016 Dec;11(12):2112-2119
pubmed: 27687962
Physiol Rev. 2001 Apr;81(2):629-83
pubmed: 11274341
J Sex Med. 2019 Aug;16(8):1178-1187
pubmed: 31351659
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Mol Cancer Res. 2010 Aug;8(8):1164-72
pubmed: 20663860
Cell Div. 2010 May 13;5:11
pubmed: 20465793
Endocrinology. 2001 Apr;142(4):1380-5
pubmed: 11250916
Cancer Discov. 2020 Aug;10(8):1103-1120
pubmed: 32690542
Cancer Res. 2002 Aug 15;62(16):4623-9
pubmed: 12183418
Oncogene. 2012 Dec 6;31(49):5117-22
pubmed: 22286761
Methods Mol Biol. 2003;229:43-55
pubmed: 12824620
Oncogene. 2015 Jan 2;34(1):73-83
pubmed: 24336325
J Neuroendocrinol. 2004 Apr;16(4):362-4
pubmed: 15089975
Clin Cancer Res. 2006 Dec 1;12(23):6869-75
pubmed: 17145803
Expert Opin Drug Saf. 2016 Sep;15(9):1163-73
pubmed: 27159501
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867
Cell. 2005 Aug 12;122(3):421-34
pubmed: 16096061
Lancet Oncol. 2018 Mar;19(3):e161-e172
pubmed: 29508763
Horm Behav. 2019 May;111:60-69
pubmed: 30713102
J Natl Cancer Inst. 2017 Mar 1;109(3):1-9
pubmed: 28376202
Cancer Res. 2011 Feb 1;71(3):873-83
pubmed: 21245096